Edesa Biotechの簿価
Edesa Biotechの簿価 は何ですか。
Edesa Biotech, Inc.の簿価 は1.77です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
NASDAQのセクタHealth Careにおける簿価 の企業と比べるEdesa Biotech
Edesa Biotechは何をしますか。
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotechと類似の簿価
- Sky Solarの簿価 は1.76です。
- Patriot National Bancorp Incの簿価 は1.76です。
- INmune Bioの簿価 は1.77です。
- Extraction Oil & Gasの簿価 は1.77です。
- Logic Instrument S.Aの簿価 は1.77です。
- LINK Mobility ASAの簿価 は1.77です。
- Edesa Biotechの簿価 は1.77です。
- Lifestyle Internationalの簿価 は1.77です。
- Naked Wines plcの簿価 は1.77です。
- Dicerna Pharmaceuticals Incの簿価 は1.77です。
- Vulcan Resourcesの簿価 は1.77です。
- Gold Rush Caribooの簿価 は1.77です。
- Westwater Resources Incの簿価 は1.77です。